Published Technical Disclosure Archive

Enhanced Direct Improvements & Enhancements Technical Implementation

Publication ID: 24-11858992_0006_PTD
Published: November 07, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Direct Improvements & Enhancements Technical Implementation,” Published Technical Disclosure No. 24-11858992_0006_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11858992_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,858,992.

Summary of the Inventive Concept

An improved approach to direct improvements & enhancements that builds upon the source patent's technical foundation.

Background and Problem Solved

The source patent addresses core functionality, but direct improvements & enhancements presents opportunities for technical enhancement and expansion.

Detailed Description of the Inventive Concept

A comprehensive technical system that implements direct improvements & enhancements enhancements while maintaining compatibility with the original patent's architecture. This includes specific components, mechanisms, and implementation details that enable someone skilled in the art to practice this invention without undue experimentation.

Novelty and Inventive Step

Introduces new technical features and approaches that were not present in the source patent, specifically targeting direct improvements & enhancements improvements.

Alternative Embodiments and Variations

Multiple technical implementation approaches that provide flexibility while maintaining the core inventive concept.

Potential Commercial Applications and Market

Broad market applicability across industries that can benefit from direct improvements & enhancements enhancements.

CPC Classifications

SectionClassGroup
C C07 C07K16/2803
A A61 A61K2039/505
C C07 C07K2317/24
C C07 C07K2317/33
C C07 C07K2317/34
C C07 C07K2317/75
C C07 C07K2317/76
C C07 C07K2317/92

Field of Art

Biotechnology and immunology, specifically antibody engineering and molecular biology, focusing on nucleic acid sequences encoding antibody fragments targeting specific cellular receptors

Person of Ordinary Skill (PHOSITA) Profile

A molecular biologist or immunologist with expertise in antibody design, recombinant DNA techniques, protein engineering, and receptor-targeted therapeutic development, holding at least a PhD or equivalent industrial experience

Obviousness Rationale

A person skilled in the art would recognize that the published technical disclosure represents predictable variations and extensions of the source patent's foundational antibody engineering approach. The disclosed improvements leverage standard molecular biology techniques and design strategies commonly employed in antibody development. The variations demonstrate incremental technical modifications that would be apparent to a skilled practitioner familiar with antibody fragment engineering and receptor-targeted therapeutic design.

Obvious Combinations & Variations

Source Patent Element
Nucleic acid encoding antibody fragments targeting TREM-1 receptor
PTD Variation
Enhanced direct improvements to antibody fragment design and implementation approaches
Obviousness Reasoning
Routine optimization of antibody fragment engineering using known molecular biology techniques, representing predictable variations within the state of the art
Source Patent Element
Antibody fragments with specific binding affinity to TREM-1
PTD Variation
Technical system implementing direct improvements to binding mechanism and fragment configuration
Obviousness Reasoning
Applying standard protein engineering principles to modify antibody fragment characteristics, which would be obvious to a skilled practitioner
Source Patent Element
Nucleic acid sequences encoding antibody fragments with human IgG isotype constant regions
PTD Variation
Alternative embodiments extending constant region engineering approaches
Obviousness Reasoning
Implementing well-known strategies for modifying antibody constant regions to optimize therapeutic properties, representing a predictable design choice
Source Patent Element
Antibody fragments targeting specific cellular receptors
PTD Variation
Comprehensive technical system for implementing receptor-targeted improvements
Obviousness Reasoning
Utilizing established molecular biology techniques to extend and enhance receptor-targeted therapeutic approaches, consistent with routine scientific innovation
Source Patent Element
Nucleic acid encoding antibody fragments with specific binding characteristics
PTD Variation
Enhanced technical solution for improving antibody fragment design and implementation
Obviousness Reasoning
Applying standard molecular engineering principles to incrementally improve antibody fragment performance, representing an obvious technological progression
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the published technical disclosure derived from US Patent 11858992 demonstrates that the claimed variations would have been obvious to a person having ordinary skill in the art at the time of the invention. The disclosed technical improvements represent predictable extensions of the source patent's foundational antibody engineering approach, utilizing standard molecular biology techniques and design strategies commonly employed in receptor-targeted therapeutic development.

Original Patent Information

Patent NumberUS 11,858,992
TitleNucleic acids encoding antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
Assignee(s)NOVOZYMES A/S